APAC Colorectal Cancer Diagnostics Market - Industry Trends and Forecast to 2030
- Published Date: 2023-08-18
- Report ID: 144915
- Pages: 250
-
Format:
The Asia-Pacific colorectal cancer diagnostics market is projected to register a substantial CAGR of 9.0% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Asia-Pacific Colorectal Cancer Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Stool Examination, Blood Test, Imaging Test, Tumor Markers, Biopsy, and Others), Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Age Group (Geriatric, Adults, and Pediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others), Country (China, India, Japan, South Korea, Thailand, Singapore, Indonesia, Malaysia, Philippines, Australia, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2030
Some of the factors that can affect the growth of the market are:
Initiatives by the government and other authorities for life sciences and funding
Increasing diagnostic products for colorectal cancer
Market Players:
The key market players in Asia-Pacific colorectal cancer diagnostics market are listed below:
F. Hoffmann-La Roche Ltd
Koninklijke Philips N.V.
Thermo Fisher Scientific Inc.
Illumina, Inc.
Quest Diagnostics Incorporated
CANON MEDICAL SYSTEMS CORPORATION
Bio-Rad Laboratories, Inc.
Merck KGaA
FUJIFILM Corporation
Agilent Technologies, Inc.
BD
Siemens Healthcare GmbH
Abbott
Neusoft Corporation
BioFire Diagnostics
Myriad Genetics Inc.
QIAGEN
Hologic, Inc.
Time Medical Holding.
PlexBio
GE HealthCare.
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF THE ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET 44
1.4 LIMITATIONS 46
1.5 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 CURRENCY AND PRICING 51
2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
2.6 MULTIVARIATE MODELLING 55
2.7 PRODUCT TYPE LIFELINE CURVE 55
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.9 DBMR MARKET POSITION GRID 57
2.10 MARKET END USER COVERAGE GRID 58
2.11 VENDOR SHARE ANALYSIS 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 64
4.1 PORTERS FIVE FORCES 65
4.2 PESTEL ANALYSIS 66
5 INDUSTRY INSIGHTS: 67
6 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 68
6.1 REGULATORY SCENARIO IN THE U.S 68
6.2 REGULATORY SCENARIO IN AUSTRALIA 68
6.3 REGULATORY SCENARIO IN JAPAN 69
6.4 REGULATORY SCENARIO IN CHINA 69
7 MARKET OVERVIEW 71
7.1 DRIVERS 73
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 73
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 73
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 73
7.2 RESTRAINTS 74
7.2.1 STRINGENT REGULATORY POLICIES 74
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 74
7.3 OPPORTUNITIES 75
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 75
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 76
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 76
7.4 CHALLENGES 77
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 77
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 78
8 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 79
8.1 OVERVIEW 80
8.2 INSTRUMENTS 83
8.2.1 PATHOLOGY-BASED INSTRUMENTS 84
8.2.1.1 PCR INSTRUMENTS 84
8.2.1.2 SLIDE STAINING SYSTEMS 84
8.2.1.3 TISSUE PROCESSING SYSTEMS 85
8.2.1.4 CELL PROCESSORS 85
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 85
8.2.2 IMAGING INSTRUMENTS 85
8.2.2.1 ULTRASOUND SYSTEMS 85
8.2.2.2 CT SYSTEMS 85
8.2.2.3 MRI SYSTEMS 86
8.2.2.4 OTHERS 86
8.2.3 BIOPSY INSTRUMENTS 86
8.2.4 OTHERS 86
8.3 CONSUMABLES & ACCESSORIES 86
8.3.1 KITS 87
8.3.1.1 PCR KITS 87
8.3.1.2 DNA POLYMERASE KITS 87
8.3.1.3 NUCLEIC ACID ISOLATION KITS 87
8.3.1.4 OTHERS 88
8.3.2 REAGENTS 88
8.3.2.1 ASSAYS 88
8.3.2.2 BUFFERS 88
8.3.2.3 PRIMERS 88
8.3.2.4 OTHERS 88
8.3.3 OTHER CONSUMABLES 88
9 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 89
9.1 OVERVIEW 90
9.2 STOOL EXAMINATION 93
9.3 BLOOD TEST 93
9.3.1 COMPLETE BLOOD COUNT (CBC) 94
9.3.2 TUMOR MARKER TEST 95
9.3.3 LIVER ENZYME BLOOD TEST 95
9.4 IMAGING TEST 95
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 96
9.4.2 MRI 96
9.4.3 ULTRASOUND 96
9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 97
9.4.5 OTHERS 97
9.5 TUMOR MARKERS 97
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 98
9.5.2 CA19-9 BIOMARKER TEST 98
9.5.3 CA 50 MARKER TEST 98
9.5.4 OTHERS 98
9.6 BIOPSY 98
9.7 OTHERS 99
10 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 100
10.1 OVERVIEW 101
10.2 STAGE III 104
10.3 STAGE IV 104
10.4 STAGE II 105
10.5 STAGE I 106
10.6 STAGE 0 106
11 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 108
11.1 OVERVIEW 109
11.2 GERIATRIC 112
11.3 ADULTS 112
11.4 PEDIATRIC 113
12 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 115
12.1 OVERVIEW 116
12.2 ADENOCARCINOMA 119
12.3 COLORECTAL LYMPHOMA 119
12.4 GASTROINTESTINAL STROMAL TUMORS 120
12.5 CARCINOID TUMORS 121
12.6 OTHERS 121
13 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 123
13.1 OVERVIEW 124
13.2 HOSPITALS 127
13.3 DIAGNOSTIC CENTERS 127
13.4 CANCER RESEARCH CENTERS 128
13.5 AMBULATORY SURGICAL CENTERS 129
13.6 ACADEMIC INSTITUTES 129
13.7 OTHERS 130
14 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION 132
14.1 ASIA-PACIFIC 133
14.1.1 CHINA 143
14.1.2 INDIA 148
14.1.3 JAPAN 153
14.1.4 SOUTH KOREA 158
14.1.5 THAILAND 163
14.1.6 SINGAPORE 168
14.1.7 INDONESIA 173
14.1.8 MALAYSIA 178
14.1.9 PHILIPPINES 182
14.1.10 AUSTRALIA 188
14.1.11 VIETNAM 193
14.1.12 REST OF ASIA-PACIFIC 198
15 ASIA PACIFIC COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 199
15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 199
16 SWOT ANALYSIS 200
17 COMPANY PROFILE 201
17.1 F. HOFFMANN- LA ROCHE LTD 201
17.1.1 COMPANY SNAPSHOT 201
17.1.2 REVENUE ANALYSIS 201
17.1.3 COMPANY SHARE ANALYSIS 202
17.1.4 PRODUCT PORTFOLIO 202
17.1.5 RECENT DEVELOPMENT 202
17.2 KONINKLIJKE PHILIPS N.V. 203
17.2.1 COMPANY SNAPSHOT 203
17.2.2 REVENUE ANALYSIS 203
17.2.3 COMPANY SHARE ANALYSIS 204
17.2.4 PRODUCT PORTFOLIO 204
17.2.5 RECENT DEVELOPMENT 204
17.3 THERMO FISHER SCIENTIFIC INC. 206
17.3.1 COMPANY SNAPSHOT 206
17.3.2 REVENUE ANALYSIS 206
17.3.3 COMPANY SHARE ANALYSIS 207
17.3.4 PRODUCT PORTFOLIO 207
17.3.5 RECENT DEVELOPMENT 207
17.4 ILLUMINA, INC. 208
17.4.1 COMPANY SNAPSHOT 208
17.4.2 REVENUE ANALYSIS 208
17.4.3 COMPANY SHARE ANALYSIS 209
17.4.4 PRODUCT PORTFOLIO 209
17.4.5 RECENT DEVELOPMENT 209
17.5 QUEST DIAGNOSTICS INCORPORATED 210
17.5.1 COMPANY SNAPSHOT 210
17.5.2 REVENUE ANALYSIS 210
17.5.3 COMPANY SHARE ANALYSIS 211
17.5.4 PRODUCT PORTFOLIO 211
17.5.5 RECENT DEVELOPMENT 211
17.6 ABBOTT 212
17.6.1 COMPANY SNAPSHOT 212
17.6.2 REVENUE ANALYSIS 212
17.6.3 PRODUCT PORTFOLIO 213
17.6.4 RECENT DEVELOPMENT 213
17.7 AGILENT TECHNOLOGIES, INC. 214
17.7.1 COMPANY SNAPSHOT 214
17.7.2 REVENUE ANALYSIS 214
17.7.3 PRODUCT PORTFOLIO 215
17.7.4 RECENT DEVELOPMENT 215
17.8 BD 216
17.8.1 COMPANY SNAPSHOT 216
17.8.2 REVENUE ANALYSIS 216
17.8.3 PRODUCT PORTFOLIO 217
17.8.4 RECENT DEVELOPMENT 217
17.9 BEIJING O&D BIOTECH CO., LTD. 218
17.9.1 COMPANY SNAPSHOT 218
17.9.2 PRODUCT PORTFOLIO 218
17.9.3 RECENT DEVELOPMENT 218
17.10 BIOFIRE DIAGNOSTICS 219
17.10.1 COMPANY SNAPSHOT 219
17.10.2 REVENUE ANALYSIS 219
17.10.3 PRODUCT PORTFOLIO 220
17.10.4 RECENT DEVELOPMENT 220
17.11 BIO-RAD LABORATORIES, INC. 221
17.11.1 COMPANY SNAPSHOT 221
17.11.2 REVENUE ANALYSIS 221
17.11.3 PRODUCT PORTFOLIO 222
17.11.4 RECENT DEVELOPMENT 222
17.12 CANON MEDICAL SYSTEMS CORPORATION. 223
17.12.1 COMPANY SNAPSHOT 223
17.12.2 REVENUE ANALYSIS 223
17.12.3 PRODUCT PORTFOLIO 224
17.12.4 RECENT DEVELOPMENT 224
17.13 FONAR CORP. 225
17.13.1 COMPANY SNAPSHOT 225
17.13.2 REVENUE ANALYSIS 225
17.13.3 PRODUCT PORTFOLIO 226
17.13.4 RECENT DEVELOPMENT 226
17.14 FUJIFILM CORPORATION 227
17.14.1 COMPANY SNAPSHOT 227
17.14.2 REVENUE ANALYSIS 227
17.14.3 PRODUCT PORTFOLIO 228
17.14.4 RECENT DEVELOPMENT 228
17.15 GE HEALTHCARE. 229
17.15.1 COMPANY SNAPSHOT 229
17.15.2 REVENUE ANALYSIS 229
17.15.3 PRODUCT PORTFOLIO 230
17.15.4 RECENT DEVELOPMENT 230
17.16 HOLOGIC, INC. 231
17.16.1 COMPANY SNAPSHOT 231
17.16.2 REVENUE ANALYSIS 231
17.16.3 PRODUCT PORTFOLIO 232
17.16.4 RECENT DEVELOPMENT 232
17.17 MEDONICA CO. LTD 233
17.17.1 COMPANY SNAPSHOT 233
17.17.2 PRODUCT PORTFOLIO 233
17.17.3 RECENT DEVELOPMENT 233
17.18 MERCK KGAA 234
17.18.1 COMPANY SNAPSHOT 234
17.18.2 REVENUE ANALYSIS 234
17.18.3 PRODUCT PORTFOLIO 235
17.18.4 RECENT DEVELOPMENT 235
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 236
17.19.1 COMPANY SNAPSHOT 236
17.19.2 PRODUCT PORTFOLIO 236
17.19.3 RECENT DEVELOPMENT 236
17.20 MYRIAD GENETICS, INC. 237
17.20.1 COMPANY SNAPSHOT 237
17.20.2 REVENUE ANALYSIS 237
17.20.3 PRODUCT PORTFOLIO 238
17.20.4 RECENT DEVELOPMENT 238
17.21 NEUSOFT CORPORATION 239
17.21.1 COMPANY SNAPSHOT 239
17.21.2 REVENUE ANALYSIS 239
17.21.3 PRODUCT PORTFOLIO 240
17.21.4 RECENT DEVELOPMENT 240
17.22 PLEXBIO 241
17.22.1 COMPANY SNAPSHOT 241
17.22.2 PRODUCT PORTFOLIO 241
17.22.3 RECENT DEVELOPMENT 241
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
